Gilead Sciences is working to shore up its rheumatoid arthritis (RA) and lupus assets, teaming up with EVOQ Therapeutics to work on treatments for the two diseases. Read More

Drugmakers spent more than $68 billion for the top acquisitions in 2022 and the biggest buyout by far was Amgen’s, announced just weeks before the year’s end. Read More

Astellas Pharma, Pfizer’s Medivation subsidiary and Regents of the University of California have filed a lawsuit alleging that Sun Pharmaceutical infringed on a patent for their blockbuster prostate cancer drug Xtandi (enzalutamide). Read More

Gilead Sciences subsidiary Kite Pharma has entered into a purchase deal with Tmunity Therapeutics — the company founded by CAR-T cell pioneer Carl June — gaining access to Tmunity’s “armored” CAR-T cell platform. Read More

Japan’s Takeda is acquiring Nimbus Therapeutics subsidiary Nimbus Lakshmi and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858 in a deal worth up to $6 billion. Read More

In 2021, manufacturers boosted the cost of seven of the country’s most expensive drugs by more than $805 million without any evidence supporting the price hikes, the Institute for Clinical and Evidence Review (ICER) reports in its latest annual cost analysis. Read More

Summit Therapeutics has acquired licensing rights for Akeso’s ivonescimab, an antibody that targets both programmed cell death receptor 1 (PD-1) and vascular endothelial growth factor (VEGF) in patients with nonsmall-cell lung cancer (NCSLC). Read More